All News

COVID-19 patients had reduced absolute granulocyte, monocyte, and lymphocyte counts at 10 months post-infection compared to noninfected individuals.

Look back at some of the amazing insights during McKesson ideaShare, the premier event for community pharmacists.

Researchers compared health care and prescription medication affordability during the COVID-19 pandemic to pre-pandemic numbers.

Farron Dozier, former sergeant first class in the US Army, sat down with Drug Topics on a recent episode of Over the Counter to discuss his experience with PTSD.

In case you missed it, this week we had news about FTC-backed PBM investigations, FDA approvals in atopic dermatitis, misconceptions about dry eye, and more.

Researchers aimed to address the extent of stigmatization’s effect on the mental health of adolescents with chronic skin disorders.

Pfizer joins Eli Lilly and Novo Nordisk in the development of oral GLP-1 receptor agonist candidates.

Global coverage for diphtheria, tetanus, and pertussis has reached its lowest point in 15 years.

“They may not understand. But I tell people, ‘I don't want you to understand me.’ I don't understand me. But if you can relate to me, then that furthers our conversation—the relatedness,” said Farron Dozier on his experience with PTSD.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

A former sergeant first class in the US Army discussed PTSD in an exclusive interview with Drug Topics.

The commercial product is expected to be available by the end of July.

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

Chris Cella, RPh, vice president of RxOwnership at McKesson, talks about how independent pharmacies can help improve their bottom line.

McKesson’s private brand of OTC health and wellness products are a great way for independent pharmacies to increase profits.

The FTC released its interim report detailing PBM practices, staggering market consolidation statistics, and the disparities between PBMs and their smaller competitors.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Researchers addressed the association between semaglutide use and the risk of nonarteritic anterior ischemic optic neuropathy.

“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Catch up on important continuous glucose monitoring (CGM) news from the month of June.

In case you missed it, this week we had news about mosquito-associated health risks, the link between cannabis and COVID-19, user experience in continuous glucose monitoring, and more.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Through a test-and-treat approach, patients who test positive for HCV RNA with the Xpert HCV test and GeneXpert Xpress System can be connected to care as soon as the same health care visit.